4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

Georgina V. Long; Jacob Schachter; Antoni Ribas; Ana M. Arance; Jean-Jacques Grob; Laurent Mortier; Adil Daud; Matteo S. Carlino; Catriona M. McNeil; Michal Lotem; James M. G. Larkin; Paul Lorigan; Bart Neyns; Christian U. Blank; Teresa M. Petrella; Omid Hamid; James Anderson; Clemens Krepler; Nageatte Ibrahim; Caroline Robert

Journal Article

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

Long G
Schachter J
Ribas A
et al.

Journal of Clinical Oncology (2018) 36(15_suppl) 9503-9503

DOI: 10.1200/jco.2018.36.15_suppl.9503

N/ACitations

41Readers

Get full text

Abstract

9503Background: KEYNOTE-006 (NCT01866319) established superiority of pembro over ipi in advanced melanoma. We provide 4-y outcomes, long-term data for pts who completed 2 y pembro, and data for sec...

Cite

CITATION STYLE

APA

Long, G. V., Schachter, J., Ribas, A., Arance, A. M., Grob, J.-J., Mortier, L., … Robert, C. (2018). 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. Journal of Clinical Oncology, 36(15_suppl), 9503–9503. https://doi.org/10.1200/jco.2018.36.15_suppl.9503

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

Abstract

Cite

Register to see more suggestions